Meeting
2023 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US.
Authors
Mairead Kearney
The Healthcare Business of Merck KGaA, Darmstadt, Germany
Mairead Kearney , Hamid Mahmoudpour , Chiemeka Ike , Ambar Modh , Sebastian Monzon , Matina Fragkogianni , Ken Carson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 572)
DOI
10.1200/JCO.2023.41.6_suppl.572
Abstract #
572
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
First Author: Melissa Kirker
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
First Author: Helen H. Moon
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
First Author: Haojie Li
Poster
2018 Genitourinary Cancers Symposium
Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy.
First Author: Jason C Simeone